Canada: Intellectual Property Enforcement Guidelines: Settlements Of Proceedings Under The PM(NOC) Regulations

Last Updated: April 23 2019
Article by Marc Richard and Cole Meagher

The Competition Bureau (the "Bureau") is an independent law enforcement agency, that ensures Canadian businesses and consumers operate in a competitive and innovative market place. On March 13, 2019 the Bureau introduced its new Intellectual Property Enforcement Guidelines   ("IPEGs"). The IPEGs seek to increase transparency regarding the Bureau's application of the Competition Act as it relates to the assertion of IP rights.

Section 7.3 of the IPEGs addresses competition concerns from settlements between brand and generic parties in relation to litigation under Patented Medicines (Notice of Compliance) Regulations (the "PM(NOC) Regulations"). In particular, section 7.3 addresses the application of sections 90.1, 79 and 45 of the Competition Act to such settlements. 

The Bureau's primary focus is on whether settlements between brand and generic parties involve payments that could serve as compensation to the generic party in exchange for delaying market entry (otherwise known as "pay for delay") resulting in harm to competition. 

Unique aspects of pharmaceutical litigation under the PM(NOC) Regulations

The IPEGs recognize advantages to settling litigation under the PM(NOC) Regulations. Settlements avoid the risk of receiving an adverse outcome at trial, provide parties certainty and as well alleviates burdens on the Courts. Further, the IPEGs highlight unique elements posed by pharmaceutical litigation which may be considered when evaluating these settlements. These include the potential exposure a brand faces for damages under section 8 of the PM(NOC) Regulations, legal costs associated with complex litigation and the pricing regimes for both brand and generic products. 

Types of Settlements of Proceedings under the PM(NOC) Regulations 

The IPEGs identify three types of settlements which may arise from proceedings under the PM(NOC) Regulations, two of which may warrant an investigation by the Bureau: 

1. Entry-Split Settlement are settlements permitting generic market entry prior to patent expiry. These agreements are considered to reflect a compromise of each party's expectation of success at trial. As long as there is no consideration provided by the brand other than the entry date prior to patent expiry, the Bureau would not review these settlements under the Competition Act;   

2. Settlement with Payment involves the brand party providing compensation in addition to allowing generic market entry prior to patent expiry. The Bureau may review such a settlement under the Competition Act to determine whether it amounts to pay for delay; and 

3. Sham Settlements or Settlements Extending beyond an Exclusionary Period. Settlements, which are shams (i.e. the parties know the patent is not infringed) or settlements which extend beyond the life of a patent, may trigger a criminal investigation.   

Sections 90.1, 79 and 45 of the Competition Act

If a settlement gives rise to an investigation, it will most likely be in relation to section 90.1 and occasionally section 79 of the Competition Act. In some instances, a criminal investigation under section 45 may be triggered.  

Application of Sections 90.1 and 79 of the Competition Act 

Section 90.1 of the Competition Act prohibits agreements that substantially prevent or lessen competition. Meanwhile, section 79 prohibits abuse of a dominant position. The Bureau may apply to the Competition Tribunal (the "Tribunal") under either provision in which the Tribunal may make an order prohibiting certain action or requiring parties to take a positive action. Section 79 further permits the Tribunal to order an administrative monetary penalty. 

Section 90.1 applies to agreements between competitors or potential competitors. The Competition Act defines these actors broadly as "a person who it is reasonable to believe would be likely to compete" with respect to the relevant product "in the absence of the agreement or arrangement". Accordingly, parties to litigation under the PM(NOC) Regulations would likely fall within this definition. 

Under section 90.1, the Bureau will investigate whether a settlement has the effect of likely causing a substantial prevention or lessening of competition. The Bureau will apply a "but-for" test to determine what would have occurred but-for the settlement. This includes considering whether the brand firm and generic firm would have been likely to compete earlier than the generic entry date specified in the settlement and whether entry would have resulted in the discipline of the firm's market power through the introduction of a lower cost alternative for drug buyers. In particular, the Bureau will examine whether any payment by the brand likely had the effect of delaying generic entry.  

In determining whether payment likely had the effect of delaying a generic firm's entry, the Bureau would consider factors such as (i) the fair market value of any goods or services provided by the generic firm; (ii) the magnitude of the brand firm's section 8 exposure under the PM(NOC) Regulations; and (iii) the brand firm's expected remaining litigation costs absent settlement.

With respect to (iii), expected remaining litigation costs absent settlement may include the expected costs of a subsequent appeal, and potential adverse cost awards at the initial action and in an appeal proceeding. If the payment is within a reasonable estimate of these factors based on information known at the time the settlement was reached, the Bureau would conclude that the settlement does not raise issues under the Competition Act

Under section 90.1(4), the Bureau may also consider possible efficiencies that could be realized through the settlement, as an exception to what would otherwise be an offence under 90.1. When assessing potential efficiencies, the Bureau would consider the credibility of such claims, their link to settlement and whether these efficiencies would or could not have been achieved by settlement. 

If reviewing the settlement under section 79 of the Competition Act, the Bureau would consider possible business justifications in its determination of whether the settlement was or was part of a practice of anti-competitive acts. The Bureau indicates it will take into account a number of considerations, including the credibility of the justifications and the link to the settlement. 

Application of Section 45 of the Competition Act 

Section 45 of the Competition Act addresses conspiracies and sham agreements between parties. Settlements that clearly restrict competition beyond a patent's exclusionary potential, restrict competition of products not at issue or are made in relation to a patent parties know is not infringed may contravene section 45 of the Competition Act

Offences under section 45 may give rise to the Bureau referring the matter to the Department of Public Prosecution (the "DPP") for prosecution. This can result in a fine of $25 million and up to 14 years in prison. The IPEGs recognize it will be rare for settlements in relation to the PM(NOC) Regulations to offend section 45. 

However, even if the Bureau does not proceed with referring the matter to the DPP, it may seek a remedy in respect of the agreement under section 90.1 of the Competition Act if it is of the view that the settlement is likely to prevent or lessen competition substantially.  

In the rare circumstances where the elements of a section 45 offence are made out, the Bureau will consider whether the ancillary restraints defence under subsection 45(4) or any other defence under section 45 is made out. In such instances, it will not refer the matter to the DPP but may seek a remedy in respect of section 90.1. 

Generally, parties may approach the Bureau at any time to resolve a matter prior to referral to the DPP for prosecution. 


The new IPEGs provide additional clarity regarding how the Bureau will review pharmaceutical settlement agreements and what terms the Bureau considers to be anti-competitive. It will be important for all parties to any patent litigation settlement, in particular with respect to proceedings under the PM(NOC) Regulations, to keep the IPEGs in mind when preparing settlement terms and conditions.  

Read the original article on

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
7 Nov 2019, Seminar, Birmingham, UK

Providing content specifically tailored to the needs of GCs and Heads of Legal working in government organisations and their affiliates.

14 Nov 2019, Seminar, London, UK

Providing content specifically tailored to the needs of GCs and Heads of Legal working in government organisations and their affiliates.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions